16 results about "Endothelial Cell Growth Factor" patented technology

The present invention provides a cell population and a method for obtaining the same. The cell population of the present invention is obtained by culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a culture medium containing four or less factors selected from stem cell factor, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor, and serum.

The invention provides a functional beverage and an application thereof in anti-hypoxia. The functional beverage disclosed by the invention is obtained by compounding a lonicera caerulea extracting solution, an acanthopanax extracting solution and a schisandra chinensis extracting solution according to a specific ratio. The functional beverage can prolong the survival time of an organism in a closed hypoxia environment, relieve lung edema or hyperemia symptoms caused by hypoxia, relieve lung pathological changes caused by hypoxia, effectively reduce the levels of protein kinase B alpha, vascular endothelial cell growth factors and hypoxia-inducible factor-1 alpha in lungs, and improve the immunity of the lungs. Therefore, oxidative stress injury can be inhibited, the anti-hypoxia capability of an organism is improved, and a good anti-hypoxia effect is achieved. In addition, the functional beverage also has good biological safety, easily acceptable flavor and stable state, and is suitable for industrial popularization.

The invention relates to a toadstool bifunctional glycopeptide for targeted immunoregulation and tumor resistance, and belongs to the technical field of biology. The molecular sequence of the morchella glycopeptide provided by the invention is LPS (Fuc) PMLLPQ, and the morchella glycopeptide molecule is obtained by connecting fucose to serine hydroxyl of a peptide chain through an alpha-glucosidic bond in an O-connection glycosylation mode. The morchella glycopeptide is identified from a morchella extract obtained by extracting morchella with pectinase by taking morchella as a substrate, is derived from edible mushrooms and is safe to use; the compound can be effectively combined with TLR4 (Toll-like receptor 4), block inflammatory response and effectively combine and inhibit VEGFR2 (vascular endothelial growth factor receptor-2), and has anti-tumor activity; meanwhile, release of LPS-induced macrophage cytokines can be inhibited, and it is further shown that the morchella glycopeptide has immunoregulation and anti-tumor activity.

This invention relates to the field of biomedical materials technology, providing a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold material, its preparation method, and its applications. The preparation method includes: decellularizing adipose tissue to obtain adipose tissue decellularized scaffold; heparinizing the scaffold to obtain a heparinized adipose tissue decellularized scaffold; loading hepatocyte growth factor and vascular endothelial cell growth factor onto the scaffold to obtain a heparinized dual-growth factor adipose tissue decellularized scaffold; seeding induced pluripotent stem cell-derived hepatocytes onto the scaffold, and culturing to obtain a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold (RAT). This invention uses rat inguinal adipose tissue to prepare RAT material, which is low-cost, readily available, has a simple preparation process, and is easy to scale up. The RAT material of this invention can achieve liver tissue damage repair and hepatocyte regeneration, providing a new treatment strategy for acute liver failure.

The present application relates to the application of phospholipids in regulating angiogenesis, and the present application applies various phospholipids and products thereof to a zebrafish model to evaluate the influence of the phospholipids on the damage of intersegmental vessels (ISVs) induced by vascular endothelial cell growth factor receptor inhibitor (PTK787) and the growth of subintestinal vessels (SIVs) in the zebrafish, and it is found for the first time that phospholipids from different sources and in different forms can reverse the damage of ISVs induced by PTK787, significantly promote the growth of SIVs in the zebrafish, and increase the length of the generated blood vessels to different degrees, and have small toxic and side effects; the present application can provide candidates for preparing drugs for vascular diseases, and has a good application prospect.

The invention provides a cell population and a method for obtaining the same. A cell population according to the present invention is obtained by culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a culture medium containing serum and four or less factors selected from the group consisting of stem cell factors, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin, and vascular endothelial cell growth factors.

The purpose of the present invention is to provide a novel hair growth promoter. The features of the present invention for solving the problem are as follows. 1. A hair growth promoter containing an extract of yellow strawberry guava fruit as an active ingredient. 2. An agent for promoting vascular endothelial cell growth factor production, containing an extract of yellow strawberry guava fruit as an active ingredient. 3. A food or drink composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 4. A pharmaceutical composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 5. A hair cosmetic composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 6. A topical skin preparation composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 7. A hair growth promoter for use in oral administration, containing an aqueous ethanol extract of yellow strawberry guava fruit as an active ingredient.

The application discloses a compound with a general formula (I), a pharmaceutically acceptable salt, a hydrate or a prodrug of the compound, and application of the compound in preparation of a medicine for preventing and / or treating diseases mediated by tyrosine kinase and / or histone deacetylase. The compound can simultaneously produce a good inhibiting effect on multiple targets (especially histone deacetylase 1, histone deacetylase 6 and two tyrosine kinases (vascular endothelial cell growth factor receptor and platelet-derived growth factor receptor)), and is expected to be used in treatment of malignant tumors.

The invention relates to a preparation method and application of a PRP-plus (Platelet Rich Plasma) containing blood cells and a gel of the PRP-plus. According to the PRP-plus prepared by the invention, platelets and leukocytes in blood are 100% efficiently extracted, the concentration of the platelets and the leukocytes is constantly 4 times that of whole blood, and the PRP-plus is particularly characterized in that the concentration of erythrocytes and hemoglobin is the same as that of normal whole blood, and the PRP-plus is rich in cell growth factors and inflammation immune induction factors, so that the PRP-plus has a good application prospect. It is found that PRP-plus can promote proliferation and growth of bone marrow stromal stem cells, fibroblasts, chondrocytes, osteoblasts and vascular endothelial cells, vascular network formation and tissue regeneration and repair by up-regulating protein abundance of a hypoxia inducible factor HIF1alpha and a vascular endothelial cell growth factor VEGF in cells.

The present application relates to a kind of targeting immunoregulation and anti-tumor morchella bifunctional glycopeptide, belong to the field of biotechnology.The molecular sequence of morchella glycopeptide provided by the present application is LPS (Fuc) PMLLPQ, and the fucose of morchella glycopeptide molecule is connected to the serine hydroxyl of peptide chain by O-connection glycosylation mode with α-glycosidic bond.The morchella glycopeptide of the present application is obtained from the morchella extract extracted by pectinase with morchella as substrate, is derived from edible fungi, and is safe to use;Can effectively bind TLR4 (Toll-like receptor 4), block inflammatory response, effectively bind and inhibit VEGFR2 (vascular endothelial cell growth factor receptor-2), and has antitumor activity;It can also inhibit the release of macrophage cytokines induced by LPS, further indicating that the morchella glycopeptide of the present application has immunoregulatory and antitumor activity.

A method for culturing heart tissue by culturing a slice of the heart tissue in a culture medium, wherein the culture medium comprises fetal bovine serum (FBS), vascular endothelial cell growth factor (VEGF), and fibroblast growth factor (FGF); and applying electrical stimulation to the slice while the heart slice is in culture is provided. Methods of screening candidate therapeutic agents for therapeutic effect or cardiotoxicity using the culture system are also provided.

The invention relates to the technical field of composite platelet hydrogel, in particular to cell-loaded composite platelet hydrogel which comprises a hydrogel mixture, and the hydrogel mixture comprises methacrylated gelatin, platelet-rich lysate, endothelial cell growth factors, a photoinitiator, a cross-linking agent and a solvent. A blood vessel network is constructed through the preparation steps of preparation of methacrylated gelatin, preparation of a platelet-rich lysate, mixing preparation, PRP redissolution, 3D printing and the like, and at present, most of biological ink printing strategies are based on sacrificial microgel, firstly, sacrificial material ink is deposited and embedded into a hydrogel matrix, and the sacrificial material ink is deposited and embedded into the hydrogel matrix; the sacrificial bio-ink is then removed to obtain a hollow cardiovascular structure, these channels can be filled with endothelial cells to further obtain a biological vascular function, the mechanical properties of the platelet rich plasma gel are improved, the endothelial cells can form a microvascular network structure, and healing of chronic wounds is promoted to a greater extent.

Aspects of the disclosure relate to recombinant adenoviruses (e.g., rAAV2.7m8-KH902) encoding anti-vascular endothelial cell growth factor (VEGF) agents in a cell or subject. In some embodiments, the compositions described herein can be used to treat a subject having a disease associated with angiogenesis or aberrant VEGF activity / signaling.

The application discloses a serum-free culture medium for vascular endothelial cells and application thereof, and belongs to the technical field of cell culture. The serum-free culture medium for vascular endothelial cells comprises a basic culture medium, and further comprises human serum albumin, endothelial cell growth factor, epidermal growth factor, follicular inhibin-like recombinant protein 1, fibroblast growth factor, insulin-like growth factor, heparin sodium, hydrocortisone, L-glutamine and ascorbic acid. The serum-free culture medium has the advantages of clear components, stable quality and low cost, can promote the division and proliferation of vascular endothelial cells, can better maintain the state of endothelial cells, has high scientific research and medical application values, and can make the cultured vascular endothelial cells have the advantages of high proliferation speed, short doubling time, good cell state, high survival rate and high activity. In addition, the serum-free culture medium does not contain xenoantigen components, will not cause an immune rejection reaction with the human body, and is suitable for industrialized production of vascular endothelial cell related products.

The present invention relates to a use of Axitinib and analogs thereof in the preparation of a blood-brain barrier permeability regulator. The blood-brain barrier permeability regulator can reduce blood-brain barrier permeability, and promote recovery of a blood-brain barrier function from a pathologically impaired state to a state close to a physiological barrier. Axitinib and an analog thereof reduce blood-brain barrier permeability by inhibiting the vascular endothelial cell growth factor-phosphatidylinositol kinase-protein kinase B signaling pathway and reducing the degree to which a blood-brain barrier tight junction protein Claudin-5 / Occludin is down-regulated. The blood-brain barrier permeability regulator can be used in the treatment of a disease related to causing a change in blood-brain barrier permeability.

The invention relates to a mesenchymal stem cell hair growth liquid and a preparation method thereof. The hair growth liquid comprises mesenchymal stem cells, the mesenchymal stem cells carry Wnt-1a protein and vasoactive factors, and the vasoactive factors comprise an endothelial cell growth factor (VEGF) and angiopoietin Ang-1. According to the invention, mesenchymal stem cells are stimulated by using a traditional Chinese medicine monomer combined with a hypoxia pretreatment method, expression and secretion of Wnt-1a protein, vascular endothelial cell growth factor (VEGF) and angiogenin 1 (Ang-1) in the product are greatly improved, and the obtained hair growth liquid product can effectively promote human hair regeneration through an intradermal introduction method, so that the hair growth effect is improved. The traditional Chinese medicine composition can be used for preventing and treating alopecia caused by exuberant secretion of male hormone.